G. Perlemuter and L. Endocrinologie, diabétologie, nutrition, collection Med-line, pp.237-238, 2001.

F. Gimenez, M. Brazier, J. Galop, T. Dine, and L. Tchiakpe, Pharmacie clinique et thérapeutique, pp.2-387

W. Ganong, Physiologie médicale, traduction de la 19ème éditions américaine, De Boeck université édition, 2001, section IV, chapitre 19, pp.318-324

C. Lautier, Génétique moléculaire de la résistance à l'insuline et des maladies associées en pathologie humaine cf dossier 1 O. Communiqué de presse conjoint OMS/fédération internationale du diabète, «il faut agir contre le diabète», 2004.

S. Wild, Global Prevalence of Diabetes: Estimates for the year 2000 and projections for 2030, Diabetes Care, vol.27, issue.5, pp.1047-53, 2004.
DOI : 10.2337/diacare.27.5.1047

«. and ». Ln, martindale The complete Drug Reference, pp.324-332, 2002.

L. Perlemuter, J. L. Selam, and G. , Collin de l'Hortet. Diabète et maladies métaboliques

A. Grimaldi, Comment je conseille aux diabétiques insulinodépendants d'adapter leurs doses d'insulines. EQUILIBRE-N°210, pp.19-21, 1999.

A. Grimaldi and . Hartemann-heurtier, Diabète insulinodépendant. La revue du Praticien.-vol50, N°13, 1er septembre, pp.1473-1484, 2000.

G. Tchobroutsky, G. Slama, R. Asson, and P. Freychet, Les échecs des traitements par antidiabétiques oraux. Traité de diabétologie, Edition Pradel, pp.737-777, 1990.

R. David and . Owens, New horizons -Alternative routes for insulin therapy UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose contrai with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Nat Rev Drug Discov Lancet, vol.352, issue.17, pp.530-24837, 1998.

F. Vauzelle-kervroedan, S. Cherou-debregeas, A. Forhan, P. Fender, and E. Eschwege, Totally reimbursed care for type 2 diabetes in 1994: characteristics and follow-up, Diabetes Metab, vol.26, issue.6, pp.55-62, 2000.

C. Nationale and . Maladie, Programme de santé publique : Diabète de type 2 (Rapport sur la prise en charge des diabétiques exclusivement traités par hypoglycémiants oraux en, p.13, 1998.

B. Detournay, Managing type 2 diabetes in France: the Ecodia Survey, Diabetes and metabolism, vol.26, pp.363-369, 2000.

E. Ciszak, J. Beals, and B. Frank, Role of C-terminal B-chain residues in insulin assembly: the structure of hexameric LysB28ProB29-human insulin, Structure, vol.3, issue.6, pp.615-637, 1995.
DOI : 10.1016/S0969-2126(01)00195-2

M. Johnson, J. White, and R. Campbell, lnsulin therapy in the era of insulin analogs, U.S. Pharmacist, vol.21, pp.35-44, 1996.

S. Noble, E. Johnston, and B. Walton, lnsulin lispro: a fast-acting insulin analog. Am Fam Physician, Jan, vol.15, issue.572, pp.279-86, 1998.

D. Howey, R. Bowsher, and R. Brunelle, Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin, Lys(B28) Diabetes

J. Woodworth, D. Howey, and R. Bowsher, Pro(B29)]-human insulin (K): dose-ranging vs humulin R (H) Diabetes, Lys, 1993.

M. Trautmann, Effect of the Insulin Analogue [LYS(B28),PRO(B29)] on Blood Glucose Control, Hormone and Metabolic Research, vol.26, issue.12, pp.588-90, 1994.
DOI : 10.1055/s-2007-1001765

A. Jr, J. Brunelle, R. Koivisto, and V. , Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment, Diabetes Feb, vol.46, pp.265-70, 1997.

A. Jr, J. Brunelle, R. Keohane, and P. , Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia i patients with non-insuiin-dependent diabetes mellitus, Arch lntern Med, vol.157, pp.1249-55, 1997.

A. Jr, J. Brunelle, R. Koivisto, and V. , lmproved mealtime treatment of diabetes mellitus using an insulin analogue, Clin Ther, vol.19, issue.1, pp.62-72, 1997.

A. Pfützner, E. Küstner, and T. Forst, Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes, Experimental and Clinical Endocrinology & Diabetes, vol.104, issue.01, pp.25-30, 1996.
DOI : 10.1055/s-0029-1211418

L. Vignati and R. Brunelle, Treatment of 722 patients with type Il diabetes with insulin lispro in a 6 month crossover study, Diabetes, 1995.

L. Vignati, J. Anderson, and R. Brunelle, lmprovement of glycemic contrai with the rapidly absorbed lispro insulin analog in type 1 diabetes, Diabetologia, vol.37, issue.1, p.78, 1994.

D. Sindaco, P. Ciofetta, M. Lalli, and C. , Use of the short-acting insulin analogue lispro in intensive treatment of Type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal, Diabetic Medicine, vol.15, issue.7, pp.592-600, 1998.
DOI : 10.1002/(SICI)1096-9136(199807)15:7<592::AID-DIA625>3.0.CO;2-J

J. Anderson, . Jr, R. Brumelle, and V. Kovisto, Reduction of Postprandial Hyperglycemia and Frequency of Hypoglycemia in IDDM Patients on Insulin-Analog Treatment, Diabetes, vol.46, issue.2, pp.265-70, 1997.
DOI : 10.2337/diab.46.2.265

C. Lalli, C. Ciofetta, and P. Del-sindaco, Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime, Diabetes Care, vol.22, issue.3, pp.468-77, 1999.
DOI : 10.2337/diacare.22.3.468

!. A. Colombe, A. Murat, M. Krempf, B. Kuchly-anton, and B. Charbonnel, Improvement of blood glucose control in Type 1 diabetic patients treated with lispro and multiple NPH injections, Diabetic Medicine, vol.39, issue.4, pp.319-343, 1999.
DOI : 10.1046/j.1464-5491.1999.00077.x

P. Raskin, A. Riis, R. Guthrie, L. Jovanovic, and L. Leiter, Use of insulin aspart, a fast acting insulin analog, as the meal time insulin in the management of patients with type 1 diabetes, Diabetes Gare, vol.23, pp.583-88, 2000.

W. Berger and J. J. Grimm, Insulinothérapie : comment gérer au quotidien les variations physiologiques des besoins en insuline, 1999.

H. Hanaire-broutin, V. Melki, S. Bessières-lacombe, and J. , Tauber: « Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment », Diabetes care, p.9, 2000.

M. Ciofetta, C. Lalli, D. Sindaco, and P. , Contribution of postprandial versus interprandial blood gluose to HbA 1 c in type 1 dabetes on physiologie intensive therapy with lispro insulin at mealtime, Diabetes Gare, vol.22, pp.795-800, 1999.

E. Lilly and . Humalog®, lnsulin lispro injection (rDNA origin), 1996.

D. Howey, R. Bowsher, and R. Brunelle, Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin, Lys(B28) Diabetes, 1999.

E. Torlone, C. Fanelli, and A. Rambotti, Pharmacokinetics, pharmacodynamies and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue, Pro(B29)] in IDDM. Diabetologia, pp.713-733, 1994.

M. Jacobs, K. Kanc, and E. Keulen, The metabolic efficacy of lispro insulin analogue in a multiple injection (MIT) regimen, Neth J Med, 1995.

D. Howey, R. Bowsher, and R. Brunelle, [Lys(B28), Pro(B29)]-human insulin: Effect of injection time on postprandial glycemia, Clinical Pharmacology & Therapeutics, vol.43, issue.4, pp.459-69, 1995.
DOI : 10.1016/0009-9236(95)90060-8

M. Trautmann, Effect of the Insulin Analogue [LYS(B28),PRO(B29)] on Blood Glucose Control, LYS(B28), pp.588-90, 1994.
DOI : 10.1055/s-2007-1001765

L. Bignati, J. Anderson, R. Brunelle, F. Jefferson, and M. Richardson, lmprovement of glycemic contrai with the rapidly absorbed lispro analog in type 1 diabetes. ln: Abstracts of the 30th annual meeting of the European Association for the Study of Diabetes, Diabetologia, vol.37, p.78, 1994.

E. Lilly and . Humalog®, lnsulin lispro injection (rDNA origin), 1996.

M. Antsiferov, J. Woodworth, and A. Mayorov, Lower within patient variabiliy in postprandial glucose excursion with lispro insulin analog compared with regular insulin, Diabetes, issue.1, p.214, 1995.

D. Howey, R. Bowsher, and R. Brunelle, Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin, Lys(B28) Diabetes

R. L. Brunelle, J. Uewelyn, J. H. Anderson, E. A. Gale, and A. , Koivisto: « Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes », Diabetes care, p.10, 1998.

V. Peragallo-dittko, K. Godley, and J. Meyer, A core curriculum for diabetes education Chicago: American Association of Diabetes Educators, pp.351-72, 1993.

R. Brunelle, J. Llewelyn, and J. Anderson, Meta-analysis of the effect of insulin lispro on severe hypoglycaemia patients with type 1 diabetes, Diabet Gare, vol.21, pp.1726-1757, 1998.

S. Heller, S. Amiel, and P. Mansell, Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycaemia during intensified insulin therapy, Diabetes Gare, vol.22, pp.1607-1618, 1999.

R. Brunelle and J. Llewelyn, Humalog reduces the incidence of severe hypoglycemia in IDDM patients, Diabetologia, vol.40, issue.1, p.61, 1997.

R. Brunelle, S. Symanowski, A. Jr, and J. , Less nocturnal hypoglycemia with insulin lispro in comparison tu human regular, Diabetes, vol.441, p.111, 1995.

J. Holcombe, S. Zalani, and V. Arora, lnsulin lispro results in less nocturnal hypoglycemia compared with regular human insulin in adolesents with type 1 dbetes, Diabetes, vol.46, p.103, 1997.

J. Tuominen, S. Karonen, and . Melamie, Exercise-induced hypoglycaemia in IDDM patients treated with a short-acting insulin analogue, Diabetologia, vol.304, issue.Suppl 1, pp.106-117, 1995.
DOI : 10.1007/BF02369359

J. Tuominen, S. Karonen, L. Melamies, G. Bolli, and V. A. Koivisto, Exercise-induced hypoglycaemia in IDDM patients treated with a short-acting insulin analogue, Diabetologia, vol.304, issue.Suppl 1, pp.106-117, 1995.
DOI : 10.1007/BF02369359

N. Fineberg, S. Fineberg, J. Anderson, M. Birkett, R. Gibson et al., Immunologic Effects of Insulin Lispro [Lys (B28), Pro (B29) Human Insulin] in IDDM and NIDDM Patients Previously Treated With Insulin, Diabetes, vol.45, issue.12, pp.1750-1754, 1996.
DOI : 10.2337/diab.45.12.1750

M. Balsells, R. Corcoy, D. Mauricio, J. Morales, A. Garcia-patterson et al., A: lnsulin antibody response ta a short course of human insulin therapy in women with gestational diabetes, Diabetes Gare, vol.20, pp.1172-1175, 1997.

L. Jovanovic, S. Pettitt, and D. , Metabolic and immunologie effects of insulin lispro in gestational diabetes, Diabetes Gare, vol.22, pp.1422-1427, 1999.

A. Bhattacharyya, S. Brown, S. Hughes, and P. A. , Insulin lispro and regular insulin in pregnancy, QJM, vol.94, issue.5, pp.255-260, 2001.
DOI : 10.1093/qjmed/94.5.255

C. Bradley, Diabetes Treatment Satisfaction Questionnaire (DTSQ) ln: Bradley C, ed. Handbook of Psychology and Diabetes, pp.111-143, 1994.

W. D. Lougheed, B. Zinman, T. Strack, and B. H. Frank, chemical stability of insulin lispro in insulin infusion system, Diabetes, Abstract book: 55th Annual meeting, 1996.

A. Bernstein, B. H. Korbas, and . Frank, stability of insulin lispro in insulin Infusion System, Diabetes Care, vol.20, p.7, 1997.

R. Renner, M. Pfutzner, O. Trautmann, . Harzer, R. Sauter et al., Use of insulin lispro in continuous subcutaneous insulin infusion treatment" l Diabetes care, p.5, 1999.

J. Radziuk, B. Bradley, and L. Welsh, Neutra! protamine lispro : activity profile of s.c. administration with and without admixture of soluble lispro, Diabetologia, vol.39, issue.1, p.224, 1996.

K. Rave, L. Heinemann, and L. Puhl, Premixed formulations of insulin lispro. Activity profiles in type 1 diabetic patients, Diabetes Care, vol.22, issue.5, pp.865-871, 1999.
DOI : 10.2337/diacare.22.5.865

T. Heise, C. Weyer, and A. Serwas, Time-Action Profiles of Novel Premixed Preparations of Insulin Lispro and NPL Insulin, Diabetes Care, vol.21, issue.5, pp.800-803, 1998.
DOI : 10.2337/diacare.21.5.800

K. Rave, L. Heinemann, and L. Puhl, Premixed formulations of insulin lispro. Activity profiles in type 1 diabetic patients, Diabetes Care, vol.22, issue.5, pp.865-871, 1999.
DOI : 10.2337/diacare.22.5.865

V. Koivisto, J. Tuominen, and P. Ebeling, Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients, Diabetes Care, vol.22, issue.3, pp.459-62, 1999.
DOI : 10.2337/diacare.22.3.459

J. Malone, V. Arora, and J. Woodwarth, Improved postprandial glycemic control with humalog?? mix75/25??? after a standard test meal in patients with type 2 diabetes mellitus, Clinical Therapeutics, vol.22, issue.2, pp.222-252, 2000.
DOI : 10.1016/S0149-2918(00)88480-5

J. Malone, H. Yang, and J. Woodworth, Humalog®Mix25 offers better and more consistent mealtime contrai in patients with type 1 and type 2 diabetes than human insulin 30, Diabetes Metab, vol.70, issue.26, pp.481-488, 2000.

P. Roach, M. Trautmann, and V. Arora, Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro Mix25 and insulin lispro Mix50, Clinical Therapeutics, vol.21, issue.3, pp.523-557, 1999.
DOI : 10.1016/S0149-2918(00)88307-1

P. Brash, K. Shaw, . Uk-humalog-mix25-study, and . Group, Reduced nocturnal hypoglycemia with twice daily insulin lispro low mixture compared to human insulin 30/70 in patients with type 2 diabetes, Diabet Med, vol.18, issue.2, p.15, 2001.

M. Pein, J. Deibler, and P. Roach, Improved glucose control following administration of a 75% insulin lispro/25% NPL mixture in patients with type 1 diabetes, Diabetes Research and Clinical Practice, vol.50, issue.1, p.220, 2000.
DOI : 10.1016/S0168-8227(00)82209-3

C. Dr-nathalie, La macroangiopathie. Impact médecin. N°565. 1er février, pp.12-15, 2002.

L. Perlemuter and J. , Sel am

J. Dr-sophie, La rétinopathie diabétique. Impact médecin n° 565, 1er février, pp.4-5, 2002.

C. Dr-nathalie, La néphropathie. Impact médecin. N°565. 1er février, pp.5-6, 2002.

J. Dr-sophie, La neuropathie diabétique. Impact médecin n° 565, 1er février, pp.7-9, 2002.

J. Dr-sophie, Le pied diabétique. Impact médecin n° 565, 1er février, pp.9-12, 2002.

M. Ciofetta, C. Lalli, D. Sindaco, and P. , Contribution of postprandial versus interprandial blood glucose to HbA 1 c in type 1 diabetes on physiologie intensive therapy with iispro insulin at mealtime, Diabetes Gare, vol.22, pp.795-800, 1999.

E. Torlone, S. Pampanelli, and C. Lalli, Effects of the short-acting insulin analog [LYS (828),PRO (829)] on postprandial blood glucose contrai in IDDM, Diabetes Gare, vol.19, pp.945-52, 1996.

M. Ciofetta, C. Lalli, D. Sindaco, and P. , Contribution of postprandial versus interprandial blood glucose to HbA 1 c in type 1 diabetes on physiologie intensive therapy with lispro insulin at mealtime, Diabetes Gare, vol.22, pp.795-800, 1999.

B. Geremia and . Belli, lnsulin treatment and its complications. Textbook of diabetes

J. Brange and D. Owens, Monomeric insulins and their experimental and clinicat implications, Diabetes Gare, vol.13, pp.923-54, 1990.
DOI : 10.2337/diacare.13.9.923

P. Kurtzhals and L. Schaffer, Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use, Diabetes, vol.49, issue.6, pp.999-1005, 2000.
DOI : 10.2337/diabetes.49.6.999

P. Home, Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers, European Journal of Clinical Pharmacology, vol.55, issue.3, pp.199-203, 1999.
DOI : 10.1007/s002280050618

L. Heinemann and C. Kapitza, Time-action Profile of the Insulin Analogue B28Asp, Diabetic Medicine, vol.13, issue.7, pp.683-687, 1996.
DOI : 10.1002/(SICI)1096-9136(199607)13:7<683::AID-DIA144>3.0.CO;2-1

S. Kang and J. Brange, Absorption kinetics and action profiles of subcutaneously administered insu lin analogues (Asp829, Glu827, Asp810, AspB28) in healthy subjects, Diabetes Gare, vol.14, pp.1057-65, 1991.

S. Mudaliar, Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects, Diabetes Care, vol.22, issue.9, pp.1501-1507, 1999.
DOI : 10.2337/diacare.22.9.1501

L. Heinemann and C. Weyer, Comparison of the time-action profiles of U40- and U100-regular human insulin and the rapid-acting insulin analogue B28 Asp, Experimental and Clinical Endocrinology & Diabetes, vol.105, issue.03, pp.140-144, 1997.
DOI : 10.1055/s-0029-1211742

L. Heinemann and M. Rauhaus, Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart, Diabetes Care, vol.21, issue.11, pp.1910-1914, 1998.
DOI : 10.2337/diacare.21.11.1910

A. Lindholm and J. Mcewen, Clinical Pharmacokinetics and Pharmacodynamics of Insulin Aspart, Clinical Pharmacokinetics, vol.17, issue.11, pp.641-59, 2001.
DOI : 10.2165/00003088-200140090-00002

G. Brunner and S. Hirschberger, Post-prandial administration of the insulin analogue insulin aspart in patients with Type 1 diabetes mellitus, Diabetic Medicine, vol.113, issue.5, pp.371-376, 2000.
DOI : 10.1007/s001250051416

A. Rosenfalck and P. Thorsby, Improved postprandial glycaemic controls with insulin Aspart in type 2 diabetic patients treated with insulin, Acta Diabetologica, vol.37, issue.1, pp.41-47, 2000.
DOI : 10.1007/s005920070034

P. Home and A. Lindholm, Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group, Diabetes Care, vol.21, issue.11, pp.1904-1913, 1998.
DOI : 10.2337/diacare.21.11.1904

P. Raskin and R. Guthrie, Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes, Diabetes Care, vol.23, issue.5, pp.583-591, 2000.
DOI : 10.2337/diacare.23.5.583

P. Home and A. Lindohlm, Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial, Diabetic Medicine, vol.21, issue.11, pp.762-70, 2000.
DOI : 10.1007/s001250050617

B. Bode, Comparison of Insulin Aspart With Buffered Regular Insulin and Insulin Lispro in Continuous Subcutaneous Insulin Infusion: A randomized study in type 1 diabetes, Diabetes Care, vol.25, issue.3, pp.439-483, 2002.
DOI : 10.2337/diacare.25.3.439

B. Bode, Efficacy, Safety, and Pump Compatibility of Insulin Aspart Used in Continuous Subcutaneous Insulin Infusion Therapy in Patients With Type 1 Diabetes, Diabetes Care, vol.24, issue.1, pp.69-72, 2001.
DOI : 10.2337/diacare.24.1.69

L. Jacobsen and B. Sogaard, Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart, European Journal of Clinical Pharmacology, vol.56, issue.5, pp.399-403, 2000.
DOI : 10.1007/s002280000159

C. Weyer and T. Heise, Insulin Aspart in a 30/70 Premixed Formulation: Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture, Diabetes Care, vol.20, issue.10, pp.1612-1616, 1997.
DOI : 10.2337/diacare.20.10.1612

K. Hermansen and S. Vaaler, Biphasic insulin aspart 30 improves postprandial glycemic contrai, Diabetes, vol.50, issue.2, p.95, 2001.

B. Boehm and P. Home, Biphasic insulin aspart and biphasic human insulin compared in type 2 diabetic subjects, Diabetologia, vol.44, issue.1, p.210, 2001.

P. Mcsorley, P. Bell, and L. Jacobsen, Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: A double-blind crossover study in adults with type 2 diabetes mellitus, Clinical Therapeutics, vol.24, issue.4, pp.530-539, 2002.
DOI : 10.1016/S0149-2918(02)85129-3

K. Hermansen, S. Vaaler, and S. Madsbad, Postprandial glycemic control with biphasic insulin aspart in patients with type 1 diabetes, Metabolism, vol.51, issue.7, pp.896-900, 2002.
DOI : 10.1053/meta.2002.33358

B. Boehm, P. Home, J. Râstam, and J. Keiding, Safety and efficacy of long term exposure to biphasic insulin aspart compared with biphasic human 144. New long-acting insulin available, Mayo Clin Health Lett septembre, vol.19, issue.9, p.4, 2001.

J. Rosenstock, S. Schwartz, C. Clark, and . Jr, Basal Insulin Therapy in Type 2 Diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin, Diabetes Care, vol.24, issue.4, pp.631-637, 2001.
DOI : 10.2337/diacare.24.4.631

P. Raskin, L. Klaff, and R. Bergenstal, A 16-week comparison of the navel insulin analog insulin glargine (HOE 901) and NPH human insu lin used with insulin lispro in patients with type 1 diabetes, Diabetes Gare novembre, vol.23, issue.11, pp.1666-71, 2000.

J. Rosenstock, G. Park, and J. Zimmerman, Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. lnsulin Glargine (HOE 901) Type 1 Diabetes lnvestigator Group, Diabetes Gare août, vol.23, issue.8, pp.1137-1179, 2000.

. Owens-dr, Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites, Diabetes Care, vol.23, issue.6, pp.813-819, 2000.
DOI : 10.2337/diacare.23.6.813

J. Buse, lnsulin glargine (HOE901 ): first responsibilities: understanding the data and ensuring safety, Diabetes Gare mai, vol.23, issue.5, pp.576-584, 2000.

M. Koda-kimble, C. Ba-diabetes-mellitus-koda-kimble, M. Young, and L. , Applied Therapeutics: The C/inical Use of Drugs
DOI : 10.1007/978-1-349-13175-4

G. Mcevoy, American hospital formulary service. Drug information, pp.2988-90, 2001.

T. Heise, No evidence for accumulation of insulin glargine (LANTUSR): a multiple injection study in patients with Type 1 diabetes, Diabetic Medicine, vol.42, issue.6, pp.490-495, 2002.
DOI : 10.1007/s001250051286

A. Fritsche, Glimepiride Combined with Morning Insulin Glargine, Bedtime Neutral Protamine Hagedorn Insulin, or Bedtime Insulin Glargine in Patients with Type 2 Diabetes, Annals of Internal Medicine, vol.138, issue.12, pp.952-959, 2003.
DOI : 10.7326/0003-4819-138-12-200306170-00006

E. Standl, Morning versus bedtime insulin glargine in combination with glimepiride: no difference in incidence of nocturnal hypoglycemia in patients with type 2 diabetes, Diabetes, vol.52, issue.1, p.574, 2003.

M. Lepore, Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro, Diabetes, vol.49, issue.12, pp.2142-2148, 2000.
DOI : 10.2337/diabetes.49.12.2142

R. Hirsch, T. E. Mecca, and C. A. , Wilson:« efficacy and safety of insulin glargine in subjects with type 1 diabetes: A 28 week randomised, NPH insulin-controlled trial », Diabetes, Abstract book, p.516, 1999.

T. Pieber, Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes, Diabetes Gare, vol.23, p.2, 2000.

R. Ratner, Less Hypoglycemia With lnsulin Glargine in Intensive lnsulin Therapy for Type 1 Diabetes, Diabetes Gare, vol.23, p.5, 2000.

H. Yki-jarvinen, M. Dressler, and . Ziemen, Less nocturnal hypoglycemia and better post-dinner glucose contrai with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes, Diabetes Gare, vol.23, issue.8, p.1134, 2000.

R. Becker, C. Frick, and . Kapitza, Pharmacodynamies (PD) and Pharmacokinetics (PK) of lnsulin Glulisine Compared with lnsulin Lispro (IL) and Regular Human lnsulin (RHI) in Patients with Type 2 Diabetes, Abstract 503. 64th Annual Scientific Sessions, 2004.

L. Nosek, R. Becker, and . Frick, Prandial Blood Glucose Contrai with Pre-and Post-Meal lnsulin Glulisine Versus Regular Human lnsulin. Abstract 588, 64th Annual Scientific Sessions, 2004.

S. Garg, J. Rosenstock, and K. Ways, Efficacy and Safety of Post-Meal lnsulin Glulisine (GLU) Compared with Pre-Meal Regular Human lnsulin (RHI) in a Basal-Bolus Regimen with lnsulin Glargine. Abstract 529, 64th Annual Scientific Sessions, 2004.

G. Dailey, J. Rosenstock, and R. Moses, Ways K lnsulin glulisine provides improved glycemic contrai in patients with type 2 diabetes. Diabetes Gare, pp.2363-2371, 2004.

A. Frick, F. Burger, and H. Scholtz, Time-Action Profile of lnsulin Glulisine (GLU) versus Regular Human lnsulin {RHI) and lnsulin Lispro (IL) in Obese Subjects. Abstract 526, 64th Annual Scientific Sessions, 2004.

T. Danne, K. Rave, and C. Bittner, Pharmacokinetics and Safety of lnsulin Glulisine in Children and Adolescents with Type 1 Diabetes. Abstract 2538, 64th Annual Scientific Sessions, 2004.

H. Hanaire-broutin and D. Schumicki, Safety of lnsulin Glulisine Compared with lnsulin Aspart Administered by Continuous Subcutaneous lnsulin Infusion (CSll) Abstract 15-0R 64th Annual Scientific Sessions, 2004.

. Rakatzil, G. Seipke, and J. Eckel, [LysB3, GluB29] insulin: a novel insulin analog with enhanced ??-cell protective action, Biochemical and Biophysical Research Communications, vol.310, issue.3, pp.852-861, 2003.
DOI : 10.1016/j.bbrc.2003.09.090

P. Kurtzhals, L. Schâffer, and A. S0resen, Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use, Diabetes, vol.49, issue.6, pp.999-1005, 2000.
DOI : 10.2337/diabetes.49.6.999

J. Markussen, S. Havelund, and P. Kurtzhals, Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs, Diabetologia, vol.259, issue.Suppl 2, pp.281-88, 1996.
DOI : 10.1007/BF00418343

P. Kurtzhals, S. Havelund, J. 1. Markussen, and J. , Effect of Fatty Acids and Selected Drugs on the Albumin Binding of a Long-Acting, Acylated Insulin Analogue, Journal of Pharmaceutical Sciences, vol.86, issue.12, pp.1365-68, 1997.
DOI : 10.1021/js9701768

P. Strange, J. Mcgill, and M. Mazzeo, Reduced pharmacokinetic (PK) variability of a navel, long-acting insulin analog (Abstract), Diabetes, vol.48, p.103, 1999.

O. Konrad, M. Steigert, J. Et, and E. Schoenle, Lantus® et Levemir® deux nouveaux analogues d'insulines à effet prolongé, Paediatrica. Vol, vol.15, issue.4, pp.50-53, 2004.

M. Hamilton-wessler, M. Ader, D. M. Moore, and D. , Mechanism of protracted metabolic effects of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin, Diabetologia, vol.42, issue.10, pp.1254-63, 1999.
DOI : 10.1007/s001250051301

P. Kurtzhals, L. Schaffer, A. Sorensen, and C. Kristensen, Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use, Diabetes, vol.49, issue.6, pp.999-1005, 2000.
DOI : 10.2337/diabetes.49.6.999

G. Brunner, S. Hirschberger, G. Sendlhofer, A. Wutte, M. Ellmerer et al., Post-prandial administration of the insulin analogue insulin aspart in patients with Type 1 diabetes mellitus, Diabetic Medicine, vol.113, issue.5, pp.371-375, 2000.
DOI : 10.1007/s001250051416

R. , D. Bolinder, J. Simpson, R. Roberts, A. Bayer et al., Lower and more predictable fasting blood glucose and reduced risk of nocturnal hypoglycaemia with once daily insulin detemir versus NPH in subjects with type 1 diabetes Stand! Efficacy and safety of 6·-month treatment with insulin di;:;temîr in type 1 diabetic patîents on a basal, ln: European Association for the Study of Diabetes 37tl1 Annual Meeting, pp.51-180, 2001.

T. Pieber, V. Grill, A. Kristensen, and E. Draeger, Treatment with insulin detemir allows flexible timing of administration in subjects with type 1 diabetes [abstract]. ln: 1 Bth International Diabetes Federation Gongress Novo Nordisk, 2003.

L. Heinemann, K. Sinha, C. Weyer, M. Loftager, S. Hirschberger et al., Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304, Diabetic Medicine, vol.39, issue.Suppl. 1, pp.332-338, 1999.
DOI : 10.1046/j.1464-5491.1999.00081.x

T. Haak, A. Tiengo, and W. Waldhausel, Treatment with insulin detemir is associated with predictable fasting blood glucose levels and favourable weight development in subjects with type 2 diabetes, Diabetes, vol.52, issue.1, p.120, 2003.

P. Vague, J. Selam, and S. Skeie, lnsulin detemir is associated with more predictable glycaemic contrai and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart, Diabetes Gare, vol.26, issue.3, pp.590-596, 2003.

K. B. Herbst, Hirsh: « lnsulin strategies for primary care providers », Clinical diabetes, pp.11-17, 2002.

F. Shojaee-moradie, H. Eckey, N. Jackson, A. Schüttler, D. Brandenburg et al., Novel hepatoselective insulin analogues: studies with covalently linked thyroxyl insulin complex in humans, Diabetes Gare, vol.23, pp.1124-1129, 2000.

S. Clement, P. Dandona, J. Still, and G. Kosutic, Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: results from a phase I/II clinical trial, Metabolism, vol.53, issue.1, pp.54-62, 2004.
DOI : 10.1016/j.metabol.2003.07.021

R. Abbas, A. Leone-bay, R. Agawal, S. Majuru, P. Rolan et al., Oral lnsulin: Pharmacokinetics and Pharmacodynamies of Human lnsulin Following Oral Administration of an lnsulin/Delivery Agent Capsule Healthy Volunteers, Diabetes Journal of the American Diabetes Association, vol.51, issue.2, p.48, 2002.

J. Vagneur, Insuline inhalée : un espoir bien inspiré pour les diabétiques? info Respiration, p.21, 2002.

J. Skyler, Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study, The Lancet, vol.357, issue.9253, pp.357-331, 2001.
DOI : 10.1016/S0140-6736(00)03638-2

T. Heise, Time action profile of an inhaled insulin preparation in comparison to insulin lispro and regular insulin, Diabetes, issue.A10, p.39, 2000.

W. T. Cefalu, Inhaled Human Insulin Treatment in Patients with Type 2 Diabetes Mellitus, Annals of Internal Medicine, vol.134, issue.3, pp.203-210, 2001.
DOI : 10.7326/0003-4819-134-3-200102060-00011

J. C. Cappelleri, Treatment satisfaction in type 2 diabetes: A comparison between an inhaled insulin regimen and a subcutaneous insulin regimen, Clinical Therapeutics, vol.24, issue.4, pp.552-64, 2002.
DOI : 10.1016/S0149-2918(02)85131-1

R. Gerber, Treatment Satisfaction With Inhaled Insulin in Patients With Type 1 Diabetes: A randomized controlled trial, Diabetes Care, vol.24, issue.9, pp.1556-1565, 2001.
DOI : 10.2337/diacare.24.9.1556

J. Skyler, Exubera Phase Ill Study Group Efficacy and safety of inhaled insulin compared to subcutaneous insulin therapy in an intensive insulin regimen in patients with type 1 diabetes: results of 6 month, randomised, European Association for the Study of Diabetes 38 1 h Annual Meeting, 2002.

W. Cefalu, Exubera Phase Ill Study Group Mealtime rapid-acting inhaled insulin improves glycaemic contrai in patients with type 2 diabetes failing combination oral agents: a 3 month, randomised, comparative trial in European Association for the Study of, Diabetes, vol.38, p.111

A. Belanger, . Exubera-phase-ill-study, and . Group, Efficacy and safety of inhaled insulin compared to subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6 month, randomised, comparative trial in European Association for the Study of Diabetes 38th Annual Meeting, 2002.

S. J. Farr, Pulmonary Insulin Administration Using the AERx?? System: Physiological and Physicochemical Factors Influencing Insulin Effectiveness in Healthy Fasting Subjects, Diabetes Technology & Therapeutics, vol.2, issue.2, pp.185-197, 2000.
DOI : 10.1089/15209150050025131

S. J. Farr, Comparison of in vitro and in vivo efficiencies of a navel unit-dose aerosol generator and a pressurised metered dose inhaler

R. David and . Owens, New horizons -Alternative routes fo insulin therapy, Nat Rev Drug Discov, issue.17, pp.529-569, 2002.

M. Kipnes, Pharmacokinetics and pharmacodynamies of pulmonary insulin delivered via the AERx diabetes management system in type 1 diabetics. Diabeto/ogia 43, p.201, 2000.

J. Jendle, Pharmacokinetics of pulmonary insulin in healthy smokers and non-smokers, Diabetologia, vol.44, p.816, 2001.

R. Henry, Pulmonary delivery of insulin using the AERx TM insulin diabetes management system in healthy and asthmatic subjects, Diabetologia, vol.44, p.9, 2001.

D. and R. A-j-i-v-dhand, New nebuliser technology-Aerosol generation by using a vibrating mesh or plate with multiple apertures. Business briefing: long term health care strategies, pp.1-2, 2003.

A. Perera, Dose-Response Relationships of lnhaled lnsulin Delivered via the Aerodose lnsulin Inhaler and Subcutaneously lnjected lnsulin in Patients With Type 2 Diabetes, Diabetes Gare, vol.26, pp.2842-2847, 2003.

. J. Whelan, Electronic DPI for insulin, Drug Discovery Today, vol.7, issue.4, pp.213-217, 2002.
DOI : 10.1016/S1359-6446(02)02190-6

J. Hrkach, AIR insulin : complete diabetes therapy via inhalation of fastacting and slow-acting dry powder aerosols, Diabetes, vol.43, issue.1, p.37, 2000.

S. Steiner, A. Mann, and S. Steiner, Techosphere insulin: bioavailability and pharmacokinetic properties in healthy volunteers Technosphere/lnsulin--a new approach for effective delivery of human insulin via the pulmonary route, Diabetologia Diabetes Technol Ther, vol.4, issue.15, pp.43589-94, 2000.

E. Standl, A. Roberts, and H. Lang, Long-term efficacy and safety of insulin detemir in subjects with type 1 diabetes. Favorable weight development and risk reduction of nocturnal hypoglycemia [abstract]. ln: American Diabetes Association 62nd Scientific Sessions Novo Nordisk, 2002.

K. Hermansen, S. Madsbad, H. Perrild, A. Kristensen, and M. Axelsen, Comparison of the Soluble Basal Insulin Analog Insulin Detemir With NPH Insulin: A randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy, Diabetes Care, vol.24, issue.2, pp.296-301, 2001.
DOI : 10.2337/diacare.24.2.296

S. Halimi and P. Benhamou, la mise à l'insuline du diabétique noninsulinodependant , www.sante.ujf-grenoble.fr, 2004.

P. Fontaine, P. J. Guillausseau, S. Halimi, P. Vexiau, and B. , Vialettes, mise à l'insuline du diabétique non insulino-dependant, www.alfediam.org consulté en, 2004.

A. Pharma, 24-hour lantus® (insulin glargin (r-DNA origin injection), 2004.

C. Johnston and . Espe, Study compares insulin glargine with NPH insulin in children with type 1 diabetes, Adresse URL, 2004.

!. ~. @bullet-f-"-~-·-~...., ( @Jrrmrnt ~Jr \urr ? . 1 m JH' ~nrn n ùr~ mti. " itrrn flr l.a fomfü\ ~r!T r 1m!H~ Hll'rH ~w l'u1·i'irt hi~i1 µ!,~ummc lt

~. Id-'t-'xl-'rtr-r and . ~tui-t-'i-uth, rt lt ?· !ii mmt ~ iiu ta füttu·, mit +n-ufi . : ?i !! hm tu1rr nnmrtcürr t l br n·~1 vn 1.1?r uuu 1 ·ru l ~m:ru1 1. ~c lrit hdul l11n ru 11 ig.m'HI'. niai!i mm??ê !ru 1 ·1?t\lru ~ r l'l1unnr1u. ~ r h' iu·ttb itr ri ~u ~ r11itrh~· rflOEJ:'UH 1 1tL tic tl.l' iunmh1 rutblh?t Ut!l m:r.fiJHl lil.füJbihtf rf llH'! ~ l'tmini i'HHl. "t!i li' m~i l <.rt~ l~ l' t !m htunU · 11 unrn hu : ~ 1 n m1 n m nw h· IH " curHlîUft !i'ai à ultHtï r mr

L. Objectifs-de-ce-travail-ont-Été-multiples, insuline dans l'arsenal thérapeutique du diabète de type 2 et à quel· moment la proposer au patient. D'a1:Jtre part, de présenter les nouvelles insulines, issues de la technologie de l'ADN recombinant, dont la cinétique est plus proche des besoins physiologiques et q1:Ji représente un acquis significatif en termes d'amélioration de l'efticaci, té du traitement et de qualité de

L. Mots-clés, Diabète de type 2, Insulinothérapie, nouvelles insulines, nouveaux dispositifs d'administration de l'insuline